BIOTEC COMPLETES PATIENT ENROLLMENT IN DIABETIC ULCER TRIAL

Biotec Pharmacon has completed patient enrollment in a double-blinded, therapeutic exploratory clinical phase II trial to evaluate the efficacy of its soluble beta-1,3/1,6-glucan (SBG) on chronic foot ulcers in diabetic patients. The trial, which is performed at hospitals in Archangelsk and St. Petersburg, Russia, involves 60 patients.

Nettavisen (http://kurser.tv2.no/Nettavisen/iwt.dll/NewsItem?&NewsID=OBI%2F128476)